The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Parathyroid Hormone-related Protein (PTHrP), Common Genetic Variants In The PTHrP Gene (PTHLH), And Breast Cancer Risk And Survival
Funder
National Health and Medical Research Council
Funding Amount
$120,253.00
Summary
In a partnership between Peter MacCallum Cancer Centre, St Vincent's Hospital, and The University of Melbourne, we are investigating the role of PTHrP, a peptide integral to the growth and spread of Cancer. Initially thought to facilitate cancer spread, recent studies suggest it may actually be protective. In a new approach, we will analyse new DNA databases and patient data from around the world. We hope to extend our understanding of PTHrP, and perhaps find novel drug and therapeutic targets.
Cancers can induce fluid build up within the chest cavity leading to breathlessness impairing quality of life. These three studies are focused on improving MPE care. The PLEASE study aims to determine the mechanism of breathlessness and provide predictors for patient selection for fluid drainage. The AMPLE-2 trial will determine the optimal drainage regime to improve patient related outcomes. The FRAME study will evaluate the safety, tolerability and efficacy of a novel therapy in mesothelioma.
Incorporating Genomics Into Breast Cancer Management
Funder
National Health and Medical Research Council
Funding Amount
$128,224.00
Summary
This study will investigate use of genomic sequencing in advanced and early breast cancer. We will characterise genetic characteristics of patients who benefit from two different therapies in the metastatic setting. We will use circulating tumour DNA analysis to monitor for and genetically characterise minimal residual disease (MRD) in patients apparently cured by initial therapy. This will thus identify potential therapeutic targets for preventing MRD progressing to metastatic disease.
CLINICAL CHARACTERIZATION OF GENETICALLY DEFINED GERMLINE SUB-GROUPS OF MELANOMA AND BREAST CANCER PATIENTS.
Funder
National Health and Medical Research Council
Funding Amount
$140,949.00
Summary
In this project I will assess how cancer patients’ genetic makeup influences the nature and outcome of their cancer, especially in terms of how successful treatment is likely to be. We will show how key genetic variants influence cancer behaviour and by combining these genes we will have a better understanding of how to develop more successful treatments.
Despite the clear epidemiological evidence that physical activity can reduce breast cancer recurrence and risk, little is know about the mechanisms. The aim of this project is determine the metabolic pathways and immunological effects of exercise in preclinical breast cancer models and in breast cancer patients, and to determine if there are synergistic effects with current systemic therapies.
Developing Microenvironment-based Prognostic Biomarkers For Early Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$132,743.00
Summary
Approximately 20% of breast cancer patients are now diagnosed with ductal carcinoma in situ (DCIS), an early stage where tumour cells are confined within the ducts of the breast and pose no threat to life. Once cells spread beyond the duct into surrounding breast tissue, risk of spread increases dramatically. This project aims to use a unique set of patient samples to identify markers that predict DCIS patients that are most at risk of spread, to personalise therapy to and reduce over-treatment.
Automated Screening Measures Associated With Risk And Treatment (SMART) Of Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$98,244.00
Summary
Women with greater mammographic density (white area on a mammogram) are at greater risk of breast cancer. Prof Hopper (supervisor) has led international research in this area using a method called CUMULUS. Drs Makalic and Schmidt (co-supervisors) have created an automated measure, called CIRRUS. My aims are to: find out which factors influence CIRRUS, confirm that CIRRUS predicts breast cancer risk, and develop automated measures of a breast cancer risk based on magnetic resonance imaging (MRI).
Cell Survival Pathways As Potential Targets In Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$142,914.00
Summary
Cancer cells are characterised by their capacity for relentless growth, survival and evasion of cell death. This proposal will use patient derived xenograft models of primary breast cancer to test the hypothesis that addition of BH3-mimetics could improve response to anti-HER2 therapy. This technique involves transplantation of patient tumours into immune-compromised mice. This represents a useful method for testing new agents.
Quantifying Breast Cancer Over-diagnosis In An Organized Mammography Screening Program
Funder
National Health and Medical Research Council
Funding Amount
$92,314.00
Summary
While breast screening reduces breast cancer deaths by finding cancers earlier, it may also find cancers that would never have required treatment. Currently there is no clear consensus about the level over-diagnosis. This study will examine the extent of over-diagnosis by comparing the breast screening histories of women diagnosed with breast cancer and women who have not had breast cancer. Findings will inform policy on breast screening in Australia.
Psychosocial Aspects Of Genomic Testing For Breast Cancer Risk
Funder
National Health and Medical Research Council
Funding Amount
$108,902.00
Summary
Assessing a woman’s breast cancer risk by profiling polygenic risk represents a new approach in the familial cancer setting. My study is part of a program of research that aims to facilitate translation of polygenic risk information into clinical practice. For this, I will invite 400 women to receive their personal polygenic result and i) assess interest in receiving this result; ii) assess psychological and behavioural outcomes of receiving or not receiving their personal polygenic risk result